<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532519</url>
  </required_header>
  <id_info>
    <org_study_id>horcoop-hmo-ctil</org_study_id>
    <nct_id>NCT00532519</nct_id>
  </id_info>
  <brief_title>Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which
      appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin
      scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless,
      in many cases no underlying physical disease is present. According to the literature, in
      fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform
      disorders.

      We hypothesize that a group of these patients may benefit from antidepressant therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Prurigo Nodularis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram (cipralex)</intervention_name>
    <description>10-20 mg/day, for 12 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  prurigo nodularis

          -  age: 18-70 years

          -  agreed to participate

        Exclusion Criteria:

          -  younger than 18 or older than 70

          -  pregnant or lactating women

          -  chronic diseases: cancer, neurological disorders, diseases that are known to be
             associated with pruritus such as liver cirrhosis, uremia, etc.

          -  sensitivity to cipralotam

          -  psychosis, bi-polar disorder, substance addiction, use of antidepressant in the
             previous year

          -  use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>liran horev, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>rena cooper-kazaz, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liran Horev, MD</last_name>
    <phone>OO97226777111</phone>
    <email>LIRAN_CH@BEZEQINT.NET</email>
  </overall_contact>
  <location>
    <facility>
      <name>: Hadassah Medical Organization,</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arik Tzukert, DMD</last_name>
      <phone>00 972 2 6776095</phone>
      <email>arik@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>00 972 2 6777572</phone>
      <email>: lhadas@hadassah.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>September 19, 2007</last_update_submitted>
  <last_update_submitted_qc>September 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prurigo</mesh_term>
    <mesh_term>Neurodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

